Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701)

NCT01381666 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Interstitial Lung Disease

Interventions

DRUG: INS316 solution for inhalation
DRUG: hypertonic saline 3% sodium chloride solution

Sponsor

Merck Sharp & Dohme LLC